ImmuPharma plc (LON:IMM – Get Free Report) shot up 11.7% during mid-day trading on Tuesday . The company traded as high as GBX 4.39 ($0.06) and last traded at GBX 4.38 ($0.06). 5,453,036 shares traded hands during trading, a decline of 71% from the average session volume of 18,661,518 shares. The stock had previously closed at GBX 3.92 ($0.05).
ImmuPharma Stock Performance
The company has a market capitalization of £18.62 million, a PE ratio of -7.57 and a beta of 1.53. The business’s 50-day moving average is GBX 2.89 and its 200-day moving average is GBX 2.07.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- Using the MarketBeat Dividend Tax Calculator
- Hims & Hers Earnings Could Be a Game Changer—What to Do Now
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Mortgage Market Bottom? Why Rocket Companies Could Be a Buy
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
